Today the Niemann-Pick Spain Foundation came to deliver the check for 71,056.25 euros that will fully finance a pilot study to determine the efficacy and safety of the drug Efavirenz to alleviate the cognitive deterioration of patients with this minority disease of genetic origin and for which there is currently no treatment. The event was […]
This is the largest study on the genetics of colorectal cancer risk. The study, carried out by a global consortium, with the participation of IDIBELL and the Catalan Institute of Oncology, opens new strategies for treatment and chemoprevention.
Funded projects address different areas of health, from precision radiotherapy to the search for therapies for breast cancer and other diseases.
The Ministry of Science and Innovation and the State Research Agency, in the call for Grants for the Preparation and Management of European Projects, have financed the project “UPDATE – SUPporting IDIBELL reseArchers To succeed in Horizon Europe”.
Funded the UPDATE project that will promote the leadership of IDIBELL in Horizon Europe Read More »
A study by IDIBELL and the University of Amsterdam published in the journal Cell Death and Disease shows that TRAIL protein receptors induce the expression of IL-8, a protein that promotes tumor development and angiogenesis in lung tumors.
A team from IDIBELL and the Catalan Institute of Oncology has published the results of a survey that shows that anti-vaccine groups, flat earthers or defenders of the existence of reptilians recognize less the actual cancer causes, and therefore, identify false myths as carcinogens.
Based on the ‘Global Burden of Disease’ 2019, national researchers led by CIBER, and other Spanish and North American centers, including IDIBELL and ICO, draw a detailed picture of the health in Spain before the pandemic and offer a vision of the future trends.
A joint project from the UPC, the UB, the HUB, and IDIBELL studied the probability of suffering severe pneumonia, needing ventilation, or even dying during hospital admission due to COVID-19. As a result of the statistical models created, based on data from more than 5,000 patients admitted to five hospitals in different pandemic waves, they developed a web application for the early identification of potentially high-risk COVID-19 patients and the prediction of the disease course.
This support will help to develop and characterize a new immunomodulatory compound discovered by the IDIBELL group led by Dr. Josep Maria Aran.
The didactic material presented a year ago has been reviewed after its application as a pilot test with 3rd and 4th ESO students at the Virolai School and the Bellvitge Institute. The study concludes that educational programs prevent addictions to video games and gambling.
